By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Quest Diagnostics today said that its proposed acquisition of Celera has cleared US antitrust review.

The firm said that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has expired in connection with the deal, satisfying one of the conditions necessary to close the transaction.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.